摘要
目的:分析肠道微生态制剂双歧杆菌四联活菌片在2型糖尿病(T2DM)中的应用价值。方法:选取2020年5月—2022年5月陆军第七十三集团军医院收治的168例T2DM患者,按随机数字表法分为对照组(n=84,予以常规治疗)、研究组(n=84,予以常规治疗+双歧杆菌四联活菌片)。对比两组治疗前后肠道菌群水平变化、血糖与胰岛素、脂质过氧化损伤情况。结果:治疗后,研究组双歧杆菌、乳酸杆菌均高于对照组,大肠杆菌、拟杆菌均低于对照组(P<0.05);治疗后,研究组空腹血糖、空腹胰岛素、胰岛素抵抗指数、胰高血糖素均低于对照组(P<0.05);治疗后,研究组谷胱甘肽过氧化物酶(GSH-Px)、总抗氧化能力(T-AOC)均高于对照组,活性氧(ROS)低于对照组(P<0.05)。结论:微生态制剂的辅助应用能够提高T2DM患者血糖控制效果,改善胰岛β细胞功能,利于促进患者病情转归。
Objective:To analyze the application value of intestinal microecologics Combined Bifidobacterium,Lactobacillus,Enterococcus and Bacillus Cereus Tablets,Live in the treatment of type 2 diabetes mellitus(T2DM).Method:A total of 168 patients with T2DM admitted to the 73rd Army Group Hospital from May 2020 to May 2022 were selected and divided into control group(n=84,received conventional treatment)and study group(n=84,received conventional treatment+Combined Bifidobacterium,Lactobacillus,Enterococcus and Bacillus Cereus Tablets,Live)according to random number table method.The changes of intestinal flora level,blood sugar,insulin and lipid peroxidation before and after treatment were compared between the two groups.Result:After treatment,Bifidobacterium and Lactobacillus in study group were higher than those in control group,Escherichia coli and Bacteroide in study group were lower than those in control group(P<0.05).After treatment,fasting blood glucose,fasting insulin,insulin resistance index and glucagon in the study group were lower than those in the control group(P<0.05).After treatment,glutathione peroxidase(GSH-Px)and total antioxidant capacity(T-AOC)in the study group were higher than those in the control group,and reactive oxygen species(ROS)in study group was lower than that in the control group(P<0.05).Conclusion:The adjuvant application of microecologics can improve the blood sugar control effect and isletβcell function in T2DM patients,which is conducive to promoting the prognosis of patients.
作者
曾丽娟
栾丽丽
冯茜
刘雪瑜
罗林
ZENG Lijuan;LUAN Lili;FENG Qian;LIU Xueyu;LUO Lin(The 73rd Army Group Hospital,Xiamen 361000,China;不详)
出处
《中国医学创新》
CAS
2023年第20期70-73,共4页
Medical Innovation of China
关键词
2型糖尿病
肠道菌群
胰岛素抵抗
双歧杆菌四联活菌片
Type 2 diabetes mellitus
Intestinal flora
Insulin resistance
Combined Bifidobacterium,Lactobacillus,Enterococcus and Bacillus Cereus Tablets,Live
